跳至主要内容
临床试验/NCT07690917
NCT07690917招募中不适用

Quality Improvement Study of a New Generation of Whole Body PET Scanners

Memorial Sloan Kettering Cancer Center7 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2026年6月30日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
90
试验地点
7
主要终点
image quality

研究概览

简要总结

The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.

详细描述

This protocol is a quality improvement protocol intended to explore and capitalize on the advanced performance characteristics of a new total body PET scanner; the Biograph Vision Quadra manufactured by Siemens Healthineers.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Eligibility Criteria for objective #1:
  • Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules.
  • Patients who are undergoing a planned PET-CT scan at main campus of MSK.
  • Patients must be ≥ 18 years old
  • Eligibility Criteria for objective #2:
  • Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously.
  • Patients with metastatic prostate or head and neck cancer.
  • Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
  • Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
  • Patients must be ≥ 18 years old
  • Eligibility Criteria for objective #3:
  • Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer).
  • Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an [18F]-fluormisonidazole PET-CT scan at the main campus of MSK.
  • Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
  • Patients must be ≥ 18 years old

排除标准

  • Patients who suffer from claustrophobia.
  • Women who are pregnant or breast-feeding.
  • Patients < 18 years of age

结局指标

主要结局

image quality

时间窗: 3 years

Detection of any new/additional lesions on the delayed scan will be recorded using standard clinical interpretation.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验